BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 25397622)

  • 21. Invasive cribriform carcinoma of the breast: mammographic, sonographic, MRI, and 18 F-FDG PET-CT features.
    Lee YJ; Choi BB; Suh KS
    Acta Radiol; 2015 Jun; 56(6):644-51. PubMed ID: 24938660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reliability of
    Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
    AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
    Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
    Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-body MR or PET-CT?
    Schmidt GP
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S142-3. PubMed ID: 23083566
    [No Abstract]   [Full Text] [Related]  

  • 26. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast.
    Byun BH; Noh WC; Lim I; Lee SS; Cho AR; Park JA; Kim KM; Kim HA; Kim EK; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2013 Oct; 27(8):720-8. PubMed ID: 23700260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
    Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
    Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
    Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility of simultaneous 18F-FDG PET/MRI for the quantitative volumetric and metabolic measurements of abdominal fat tissues using fat segmentation.
    Im HJ; Paeng JC; Cheon GJ; Kim EE; Lee JS; Goo JM; Kang KW; Chung JK; Lee DS
    Nucl Med Commun; 2016 Jun; 37(6):616-22. PubMed ID: 26836629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory-gated ¹⁸F-FDG PET/CT for the diagnosis of liver metastasis.
    Suenaga Y; Kitajima K; Aoki H; Okunaga T; Kono A; Matsumoto I; Fukumoto T; Tanaka K; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1696-701. PubMed ID: 23768610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Speeding up PET/MR for cancer staging of children and young adults.
    Aghighi M; Pisani LJ; Sun Z; Klenk C; Madnawat H; Fineman SL; Advani R; Von Eyben R; Owen D; Quon A; Moseley M; Daldrup-Link HE
    Eur Radiol; 2016 Dec; 26(12):4239-4248. PubMed ID: 27048532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fat-constrained 18F-FDG PET reconstruction in hybrid PET/MR imaging.
    Prevrhal S; Heinzer S; Wülker C; Renisch S; Ratib O; Börnert P
    J Nucl Med; 2014 Oct; 55(10):1643-9. PubMed ID: 25168626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
    Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S
    Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.